2023 / 03

Next Paper
DOI: 10.47183/mes.2023.027

ORIGINAL RESEARCH

Estimation of mutagenic potential of the valproic acid derivative containing a tertiary amino group

Zolotoverkhaja EA, Kubarskaya LG, Bespalov AYa, Melekhova AS
About authors

Golikov Research Clinical Center of Toxicology of the Federal Medical and Biological Agency, Saint-Petersburg, Russia

Correspondence should be addressed: Ekaterina A. Zolotoverkhaja
Bekhtereva, 1, Saint-Petersburg, 192019, Russia; ur.xednay@ajahkrevotoloz.e

About paper

Funding: the study was performed as part of the State Assignment “Assessment of Effiacy and Safety of the Valproic Acid Amino Ester Substance as an Agent for Drug Treatment of the Toxin-Induced Seizures”, R&D project № 121041500281-1.

Author contribution: Zolotoverkhaja EA — study planning, in silico analysis, statistical analysis and data interpretation, manuscript writing; Kubarskaya LG — in vitro experiments, data acquisition and analysis; Bespalov AYa — synthesis of the test compound, data interpretation, manuscript editing; Melekhova AS — manuscript editing, preparing supportive documents for publishing.

Compliance with ethical standards: the study was performed in silico and in vitro, no approval by the Ethics Committee was required.

Received: 2023-06-20 Accepted: 2023-08-23 Published online: 2023-09-15
|
  1. Petrov AN, Sofronov GA, Nechiporenko SP, Somin IN. Antidoty fosfororganicheskikh otravlyayushchikh veshchestv. Rossiyskiy khimicheskiy zhurnal. 2004; 48 (2): 110–116. Russian.
  2. Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology. 2021; 190: 108352. PubMed PMID: 33035532.
  3. Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015; 4: CD001191. PubMed PMID: 25858345.
  4. Zorina VN, Evdokimova EA, Reynyuk VL. Metody profilaktiki i terapii sudorozhnogo sindroma pri otravlenii konvul'santami kholinergicheskogo ryada. Meditsina ekstremal'nykh situatsiy. 2022; (2): 14–21. Russian.
  5. Connors NJ, Harnett ZH, Hoffman RS. Comparison of current recommended regimens of atropinization in organophosphate poisoning. J Med Toxicol. 2014; 10 (2): 143–7.
  6. Bespalov AYa, Prokopenko LI, Gorchakova TL, Petrov AN, Zaytseva MA, i dr, avtory; Federal'noe gosudarstvennoe byudzhetnoe uchrezhdenie nauki «Institut toksikologii Federal'nogo medikobiologicheskogo agentstva», patentoobladatel'. Gidrokhlorid (1-metilpiperidin-4-il)-2-propilpentanoata, obladayushchiy kholinoliticheskoy i protivosudorozhnoy aktivnost'yu. Patent RF № 2714135. 12.02.2020. Russian.
  7. Melekhova AS, Petrov AN, Bespalov AYa, Belskaya AV, Melnikova MV, Zatsepin EP, i dr. Eksperimental'naya farmakoterapiya sudorozhnogo sindroma pri modelirovanii tyazhelogo otravleniya karbamatom. Medlayn.ru. 2019; 20: 294–306. Russian.
  8. Snodin DJ. Genotoxic Iimpurities: from structural alerts to qualification. Organic process research and development. 2010; 14 (4): 960–976.
  9. Fukuchi J, Kitazawa A, Hirabayashi K, Honma M. A practice of expert review by read-across using QSAR Toolbox. Mutagenesis. 2019; 34 (1): 49–54.
  10. Mortelmans K, Zeiger E. The Ames Salmonella/microsome mutagenicity assay. Mutat Res. 2000; 455 (1–2): 29–60. PubMed PMID: 11113466.
  11. Heringa MB, Harmsen DJ, Beerendonk EF, Reus AA, Krul CA, Metz DH, et al. Formation and removal of genotoxic activity during UV/H(2)O(2)-GAC treatment of drinking water. Water Res. 2011; 45 (1): 366–374. PubMed PMID: 20828782.
  12. Piegorsch WW, Simmons SJ, Margolin BH, Zeiger E, Gidrol XM, Gee P. Statistical modeling and analyses of a base-specific Salmonella mutagenicity assay. Mutat Res. 2000; 467 (1): 11–19. PubMed PMID: 10771267.
  13. Benigni R. In silico assessment of genotoxicity. Combinations of sensitive structural alerts minimize false negative predictions for all genotoxicity endpoints and can single out chemicals for which experimentation can be avoided. Regulatory Toxicology and Pharmacology. 2021; 126: 105042.
  14. Ashby J, Tennant RW. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat Res. 1991; 257 (3): 229–306.
  15. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, et al. A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab. 2005; 6 (3): 161–225 PubMed PMID: 15975040.
  16. Phillips DH, Arlt VM. Genotoxicity: damage to DNA and its consequences. EXS. 2009; 99: 87–110. PubMed PMID: 19157059.